Halberd Corporation (HALB)
| Market Cap | 635.21K -58.7% |
| Revenue (ttm) | 6.94K |
| Net Income | -1.71M |
| EPS | -0.00 |
| Shares Out | 747.30M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 400 |
| Open | 0.0009 |
| Previous Close | 0.0008 |
| Day's Range | 0.0008 - 0.0009 |
| 52-Week Range | 0.0006 - 0.0028 |
| Beta | 0.13 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About Halberd
Halberd Corporation, a biotech company, develops treatments for neurodegenerative diseases. It offers treatments for post traumatic stress disorder/chronic traumatic encephalopathy, Alzheimer’s and Parkinson’s disease, cancer, blood-borne, and cerebrospinal fluid related diseases. The company was incorporated in 2009 and is based in Jackson Center, Pennsylvania. [Read more]
Financial Performance
Financial StatementsNews
Halberd Corp. Issues Letter to Shareholders - Patented LDN+ Evolves into WatchDawg™ for Veteran Suicide Reduction
JACKSON CENTER, Pa., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Halberd Corporation (OTC: HALB) today issued the following letter to its shareholders: We hope you have had an opportunity to check out last wee...
Halberd's Traumatic Brain Injury Treatment Projects Align with New U.S. House Bill
Daniel J. Harvey and Adam Lambert Improving Servicemember Transition to Reduce Veteran Suicide Act, passed the U.S. House unanimously. JACKSON CENTER, PA / ACCESSWIRE / May 9, 2024 / Halberd Corporati...
Halberd's Patented LDN+ Drug Has Begun Pre-Pilot Trials With Military Veterans
LDN+ Drug Designed to Combat PTSD and Suicidal Ideation JACKSON CENTER, PA / ACCESSWIRE / April 30, 2024 / Halberd Corporation (OTC PINK:HALB) announced a pre-pilot study of its patented LDN+ drug wit...
Halberd's Patented Drug, LDN+, the Subject of a Limited Clinical Trial Under an Innovative Four-Company Cooperative Research and Development (CRADA) Contract
JACKSON CENTER, PA / ACCESSWIRE / April 4, 2024 / Halberd Corporation's (OTC PINK:HALB) Patented LDN+ Drug hits an enormous milestone as it enters a significant Safety Trial Protocol under a CRADA con...
Halberd and Mississippi State University to Commence Stage II Advanced TBI Nasal Spray Testing
JACKSON CENTER, PA / ACCESSWIRE / February 8, 2024 / Halberd Corporation's (OTC PINK:HALB) Traumatic Brain Injury (TBI) mitigating nasal spray testing protocols at Mississippi State University (MSU) w...
Halberd's Top Executives Join Forces with Athena GTX CEO Mark Darrah Unveiling 2024 Powerful Partnership Outlook on "The Street Reports Podcast"
JACKSON CENTER, PA / ACCESSWIRE / February 6, 2024 / Halberd Corporation's (OTC PINK:HALB) and Athena GTX's executives interviewed on "The Street Reports," discuss the relationship between Halberd and...
Halberd Corporation 2023 Year-End CEO Update and 2024 Goals
JACKSON CENTER, PA / ACCESSWIRE / January 11, 2024 / Halberd Corporation (OTC PINK:HALB) made significant advances in its technology development and accomplished major business goals during the second...
Halberd Corp. Signs Significant Revenue Sharing Agreement with Athena GTX
Athena will employ its successful history of securing government contracts, spearheading such initiatives JACKSON CENTER, PA / ACCESSWIRE / January 9, 2024 / Halberd Corporation (OTC PINK:HALB) is thr...
Halberd Corporation Signs Multi-Faceted Agreement with CrodenHealth.com
Peter Croden, CrodenHealth Chairman, previously executive with Pharmacia & Upjohn (Pfizer), Upjohn Canada, Upjohn Global Animal Health, NephRx, and Parnell Pharmaceuticals Holdings, Ltd. Endeavors to ...
Halberd Corporation Plans to Extend Research Partnership with Mississippi State University
MSU Research for Halberd to Transcend the TBI Nasal Spray JACKSON CENTER, PA / ACCESSWIRE / November 15, 2023 / Halberd Corporation (OTC PINK:HALB) is in talks with Mississippi State University (MSU) ...
Hartman, CEO, and Dr. Felder, CTO of Halberd Corp, Featured on The Street Reports Podcast
JACKSON CENTER, PA / ACCESSWIRE / October 10, 2023 / Halberd Corporation (OTC PINK:HALB) Chairman, President and CEO William A. Hartman and Chief Technology Officer, Dr Mitchell S.
Halberd's Traumatic Brain Injury (TBI) Testing Results Replicated at Mississippi State University (MSU)
JACKSON CENTER, PA / ACCESSWIRE / October 4, 2023 / Halberd Corporation's (OTC PINK:HALB) proprietary nasal spray testing results to mitigate the effects of Traumatic Brain Injury (TBI) at Mississippi...
Halberd and Athena GTX Collaborate on Advanced Traumatic Brain Injury (TBI) Monitoring and Applications for Government Contracts
JACKSON CENTER, PA / ACCESSWIRE / September 20, 2023 / Halberd Corporation (OTC PINK:HALB) and Athena GTX, Inc, of Johnston, Iowa commenced collaboration on critical development of submissions for gov...
Astounding Early Test Results of Halberd's Traumatic Brain Injury (TBI) Project at Mississippi State University (MSU)
Anecdotal Results of Halberd's Nasal Spray Reveals Demonstrably Significant Reduction of Traumatic Brain Injury Markers JACKSON CENTER, PA / ACCESSWIRE / September 6, 2023 / Halberd Corporation's (OTC...
Halberd's Successful Completion of Sampling Phase Marks Major Milestone for Project at Mississippi State University (MSU)
Novel Nasal Spray for Traumatic Brain Injury Effects Poised to Demonstrate Efficacy in Patent-Pending Product JACKSON CENTER, PA / ACCESSWIRE / August 22, 2023 / Halberd Corporation (OTC PINK:HALB) an...
Halberd-Mississippi State University (MSU) Testing of TBI Nasal Spray Progresses
Scientific Paper Presented at Research Symposium JACKSON CENTER, PA / ACCESSWIRE / August 14, 2023 / Halberd Corporation's (OTC PINK:HALB) Traumatic Brain Injury (TBI) mitigation research on Halberd's...
Halberd Corporation 2Q23 CEO Letter
JACKSON CENTER, PA / ACCESSWIRE / July 20, 2023 / Halberd Corporation (OTC PINK:HALB). During the second quarter 2023 Halberd continued its groundbreaking work on its path to creating new technology p...
Halberd CEO Mid-Quarter Update
JACKSON CENTER, PA / ACCESSWIRE / May 31, 2023 / Halberd Corporation (OTC PINK:HALB) has been progressing rapidly on several projects in so many areas that this mid-quarter update is intended to bring...
Halberd Initial Preclinical Testing Phase at Mississippi State University (MSU) Complete
MSU is ahead of schedule and continues testing program JACKSON CENTER, PA / ACCESSWIRE / May 23, 2023 / Halberd Corporation (OTC PINK:HALB) announced Mississippi State University (MSU) has completed t...
Halberd Pre-Clinical Test Protocol Approved
Testing of Nasal Spray to Counteract the Effects of Head Trauma to Begin by Month's End JACKSON CENTER, PA / ACCESSWIRE / May 9, 2023 / Halberd Corporation (OTC PINK:HALB) researchers at Mississippi S...
Halberd (HALB) Pursuing a Nasal Spray to Counteract the Effects of Head Trauma
Other Neurodegenerative Conditions may be Susceptible to Remediation through this Easily Administered Process JACKSON CENTER, PA / ACCESSWIRE / May 2, 2023 / Halberd Corporation (OTC PINK:HALB) advanc...
Halberd Corporation 1Q23 CEO Letter
JACKSON CENTER, PA / ACCESSWIRE / April 25, 2023 / Halberd Corporation (OTC PINK:HALB). The first quarter 2023 continued this extraordinarily groundbreaking path, packed with new accomplishments.
HALB CEO, CTO and YSU's Dr. Sturrus Discuss CDC, Research Discoveries etc., on "The Street Reports Podcasts" Listen Now!
JACKSON CENTER, PA / ACCESSWIRE / April 20, 2023 / Halberd Corporation's (OTC PINK:HALB) President & CEO, William A. Hartman, its Chief Technical Officer, Dr. Mitchell S.
Halberd and YSU Interviewed on CBS Affiliate WKBN 5pm News as Research Advances
JACKSON CENTER, PA / ACCESSWIRE / April 17, 2023 / Halberd Corporation's (OTC PINK:HALB) successful patent protected research being conducted at Youngstown State University (YSU) on antibiotic resista...
Halberd Begins Preclinical Testing at Mississippi State University (MSU)
JACKSON CENTER, PA / ACCESSWIRE / April 11, 2023 / Halberd Corporation (OTC PINK:HALB) has announced that preclinical testing is now underway at Mississippi State University (MSU) for its groundbreaki...